Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer

doi:10.3748/wjg.v20.i4.1067

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6441)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

457

WORD

248

HTML

3683

Figures (1-2)

217

Tables (1-4)

212

Sum=4817

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

891

Download

732

Sum=1623

Jan 28, 2014 (publication date) through Dec 19, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jan 28, 2014; 20(4): 1067-1073
Published online Jan 28, 2014. doi: 10.3748/wjg.v20.i4.1067

Open in New Tab Full Size Figure Download Figure

Figure 1 Distribution of 6-field intensity modulated radiotherapy plan. Isodose distributions are shown in three orthogonal planes through the middle of the planning target volume (PTV). The isodose levels are shown colored lines over the computed tomography images, with the green area indicating the PTV.

Open in New Tab Full Size Figure Download Figure

Figure 2 Overall survival rates, according to the Kaplan-Meier technique.

Citation: Wang X, Jin J, Li YX, Ren H, Fang H, Wang SL, Liu YP, Wang WH, Yu ZH, Song YW, Liu XF. Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer. World J Gastroenterol 2014; 20(4): 1067-1073
URL: https://www.wjgnet.com/1007-9327/full/v20/i4/1067.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i4.1067